Skip to main content
Equibles
CRDF logo

CRDF · Cardiff Oncology, Inc. · Metrics

Track CRDF — free

Use CRDF with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRDF.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.91 -0.02 (-2.23%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 11, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Management has performed an analysis and concluded that there exists a substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 11, 2026
Market Cap
$70.58M
Shares
77.80M
Volume · Oct 23 174.71K Avg daily vol (3M) 717.67K

CRDF metrics

82 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.91
Market cap
$70.58M

Price action

20 metrics
Price change (1W)
+0.7%
Price change (30D)
-26.8%
Price change (3M)
+9.3%
Price change (6M)
-47.3%
Price change (YTD)
-67.7%
Price change (1Y)
-58.9%
Trailing year
Price change (5Y)
-85.0%
52-week high
$3.21
52-week low
$0.81
Change from 52-week high
-71.7%
Change from 52-week low
+12.0%
Annualized volatility
85.8%
Annualized volatility (3M)
67.5%
Beta
1.8
RSI (14D)
33.5
Price vs SMA 50
-16.3%
Price vs SMA 200
-39.1%
Avg volume (3M)
717,669
Relative volume
0.2
Average dollar volume
$766,021

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
77.80M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
71.0×
reciprocal yield 1.4%
EV / EBITDA
—
EV / EBIT
—
P / sales
138.9×
reciprocal yield 0.7%
P / book
2.7
reciprocal yield 37.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-56.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
137.2×
reciprocal yield 0.7%
EV / revenue historical average (5Y)
71.1×
reciprocal yield 1.4%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-06-03

Profitability

9 metrics
Gross margin
—
Operating margin
-8,320.1%
Trailing 12 months
Net margin
-7,884.1%
Gross profit (TTM)
$244,632
Operating profit (TTM)
−$42.27M
Net income (TTM)
−$40.05M
Trailing 12 months
Diluted EPS (TTM)
$-0.60
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.01
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-0.62
EBITDA per diluted share (TTM)
$-0.62
Net income per diluted share (TTM)
$-0.59
Operating cash flow per diluted share (TTM)
$-0.60
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.38
Stock compensation per diluted share (TTM)
$0.08
Book value per share
$0.66

Growth

11 metrics
Revenue growth YoY
-14.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$508,000
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+2.8%
Year over year · more shares
Revenue CAGR (3Y)
+15.4%
Revenue CAGR (5Y)
+10.1%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-151.0%
Return on assets
-107.3%
Debt / equity
0.0
Current ratio
3.3
EBITDA (TTM)
−$41.91M
Free cash flow (TTM)
—
Quick ratio
3.3
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$34.52M
Latest balance sheet
Cash & equivalents
$9.20M
Total assets
$37.33M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$40.85M
Capital expenditures (TTM)
$62,000
R&D (TTM)
$25.95M
SG&A (TTM)
$16.82M
Stock compensation (TTM)
$5.22M
R&D / revenue
5,108.7%
Stock compensation / revenue
1,028.5%

Ownership (13F)

9 metrics
13F filers
105
13F filer change QoQ
-12
Institutional ownership
24.4%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
10.5%
Private-fund adviser ownership
8.7%
Active holders' share change QoQ
-5.7%
Holder tenure
8.0
Price vs estimated holder cost
-54.8%

Ownership (registered funds)

1 metrics
Index-fund ownership
6.6%

Short interest

3 metrics
Short interest
15.5%
Latest settlement · 17.2 days to cover
Days to cover
17.2d
Short-squeeze score
66 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1213037 CUSIP 14147L108 13F (30d) 12 filings 12 filers Visit website Investor relations